In This Article:
Idexx Laboratories (IDXX) reported $998.43 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 3.6%. EPS of $2.96 for the same period compares to $2.81 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.02 billion, representing a surprise of -1.77%. The company delivered an EPS surprise of +1.37%, with the consensus EPS estimate being $2.92.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Idexx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Revenue- Companion Animal Group- United States: $623.89 million compared to the $625.46 million average estimate based on two analysts. The reported number represents a change of +3.6% year over year.
-
Revenue- Companion Animal Group- International: $295.95 million versus the two-analyst average estimate of $289.65 million. The reported number represents a year-over-year change of +3.1%.
-
Revenue- LPD- International: $22.81 million versus $22.09 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1% change.
-
Revenue- Water- International: $21.82 million versus the two-analyst average estimate of $21.11 million. The reported number represents a year-over-year change of +4.5%.
-
Revenue- Companion Animal Group (CAG): $919.84 million versus the four-analyst average estimate of $916.30 million. The reported number represents a year-over-year change of +3.4%.
-
Revenue- Other: $4.67 million compared to the $3.74 million average estimate based on four analysts. The reported number represents a change of +32.3% year over year.
-
Revenue- Livestock and poultry diagnostics (LPD): $28.60 million compared to the $28.12 million average estimate based on four analysts. The reported number represents a change of +1.4% year over year.
-
Revenue- Water: $45.32 million compared to the $45.27 million average estimate based on four analysts. The reported number represents a change of +5.2% year over year.
-
Revenue- CAG Diagnostics recurring revenue- IDEXX VetLab consumables: $344.78 million compared to the $333.87 million average estimate based on three analysts. The reported number represents a change of +8.8% year over year.
-
Revenue- CAG Diagnostics capital- instruments: $31.99 million versus $39.23 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.
-
Revenue- CAG Diagnostics recurring revenue- Reference laboratory diagnostic and consulting services: $344.41 million versus the three-analyst average estimate of $348.36 million. The reported number represents a year-over-year change of 0%.
-
Revenue- CAG Diagnostics recurring revenue- Rapid assay products: $84.03 million compared to the $86.26 million average estimate based on three analysts. The reported number represents a change of -2.6% year over year.